FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:474-480 August 24, 1995 Number 8 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

ABSTRACT

Background Penicillin-resistant strains of Streptococcus pneumoniae are now found worldwide, and strains with resistance to cephalosporin are being reported. The appropriate antibiotic therapy for pneumococcal pneumonia due to resistant strains remains controversial.

Methods To examine the effect of resistance to penicillin and cephalosporin on mortality, we conducted a 10-year, prospective study in Barcelona of 504 adults with culture-proved pneumococcal pneumonia.

Results Among the 504 patients, 145 (29 percent) had penicillin-resistant strains of S. pneumoniae (minimal inhibitory concentration [MIC] of penicillin G, 0.12 to 4.0 µg per milliliter), and 31 patients (6 percent) had cephalosporin-resistant strains (MIC of ceftriaxone or cefotaxime, 1.0 to 4.0 µg per milliliter). Mortality was 38 percent in patients with penicillin-resistant strains, as compared with 24 percent in patients with penicillin-sensitive strains (P = 0.001). However, after the exclusion of patients with polymicrobial pneumonia and adjustment for other predictors of mortality, the odds ratio for mortality in patients with penicillin-resistant strains was 1.0 (95 percent confidence interval, 0.5 to 1.9; P = 0.84). Among patients treated with penicillin G or ampicillin, the mortality was 25 percent in the 24 with penicillin-resistant strains and 19 percent in the 126 with penicillin-sensitive strains (P = 0.51). Among patients treated with ceftriaxone or cefotaxime, the mortality was 22 percent in the 59 with penicillin-resistant strains and 25 percent in the 127 with penicillin-sensitive strains (P = 0.64).

The frequency of resistance to cephalosporin increased from 2 percent in 1984–1988 to 9 percent in 1989–1993 (P = 0.002). Mortality was 26 percent in patients with cephalosporin-resistant S. pneumoniae and 28 percent in patients with susceptible organisms (P = 0.89). Among patients treated with ceftriaxone or cefotaxime, mortality was 22 percent in the 18 with cephalosporin-resistant strains and 24 percent in the 168 with cephalosporin-sensitive organisms (P = 0.64).

Conclusions Current levels of resistance to penicillin and cephalosporin by S. pneumoniae are not associated with increased mortality in patients with pneumococcal pneumonia. Hence, these antibiotics remain the therapy of choice for this disease.

Source Information

From the Infectious Disease (R.P., C.C., P.F.V., F.G.), Microbiology (J.L., R.M.), Internal Medicine (M.V.), and Pulmonary Disease (F.M.) Services, Hospital de Bellvitge "Princeps d'Espanya" and the University of Barcelona — both in Barcelona, Spain.

Address reprint requests to Dr. Pallares at the Infectious Disease Service, Hospital de Bellvitge "Princeps d'Espanya," 08907 L'Hospitalet, Barcelona, Spain.

Full Text of this Article

Related Letters:

Drug-Resistant Streptococcus pneumoniae
Redondo E., Clynes N., Hofmann J., Cetron M. S., Breiman R. F., Farley M. M., Pallares R., Liñares J., Gudiol F.
Extract | Full Text  
N Engl J Med 1996; 334:53-55, Jan 4, 1996. Correspondence

This article has been cited by other articles:

• Soriano, F., Cafini, F., Aguilar, L., Tarrago, D., Alou, L., Gimenez, M.-J., Gracia, M., Ponte, M.-C., Leu, D., Pana, M., Letowska, I., Fenoll, A. (2008). Breakthrough in penicillin resistance? Streptococcus pneumoniae isolates with penicillin/cefotaxime MICs of 16 mg/L and their genotypic and geographical relatedness. J Antimicrob Chemother 62: 1234-1240 [Abstract] [Full Text]  
• Tsai, M.-H., Chen, S.-H., Hsu, C.-Y., Yan, D.-C., Yen, M.-H., Chiu, C.-H., Huang, Y.-C., Lin, T.-Y. (2008). Pneumococcal Meningitis in Taiwanese Children: Emphasis on Clinical Outcomes and Prognostic Factors. J Trop Pediatr 54: 390-394 [Abstract] [Full Text]  
• MacGowan, A. P., on behalf of the BSAC Working Parties on Resistanc, (2008). Clinical implications of antimicrobial resistance for therapy. J Antimicrob Chemother 62: ii105-ii114 [Abstract] [Full Text]  
• Garcia-Vidal, C., Fernandez-Sabe, N., Carratala, J., Diaz, V., Verdaguer, R., Dorca, J., Manresa, F., Gudiol, F. (2008). Early mortality in patients with community-acquired pneumonia: causes and risk factors. Eur Respir J 32: 733-739 [Abstract] [Full Text]  
• Hsieh, Y.-C., Chang, K.-Y., Huang, Y.-C., Lin, H.-C., Ho, Y.-H., Huang, L.-M., Hsueh, P.-R. (2008). Clonal Spread of Highly {beta}-Lactam-Resistant Streptococcus pneumoniae Isolates in Taiwan. Antimicrob. Agents Chemother. 52: 2266-2269 [Abstract] [Full Text]  
• Cardoso, M. R. A, Nascimento-Carvalho, C. M, Ferrero, F., Berezin, E. N, Ruvinsky, R., Camargos, P. A M, Sant'Anna, C. C, Brandileone, M. C. C, de Fatima P March, M., Feris-Iglesias, J., Maggi, R. S, Benguigui, Y., and the CARIBE Group, (2008). Penicillin-resistant pneumococcus and risk of treatment failure in pneumonia. Arch. Dis. Child. 93: 221-225 [Abstract] [Full Text]  
• Asghar, R., Banajeh, S., Egas, J., Hibberd, P., Iqbal, I., Katep-Bwalya, M., Kundi, Z., Law, P., MacLeod, W., Maulen-Radovan, I., Mino, G., Saha, S., Sempertegui, F., Simon, J., Santosham, M., Singhi, S., Thea, D. M, Qazi, S., for the SPEAR (Severe Pneumonia Evaluation Antimic, (2008). Chloramphenicol versus ampicillin plus gentamicin for community acquired very severe pneumonia among children aged 2-59 months in low resource settings: multicentre randomised controlled trial (SPEAR study). BMJ 336: 80-84 [Abstract] [Full Text]  
• Garcia-Vidal, C., Calbo, E., Pascual, V., Ferrer, C., Quintana, S., Garau, J. (2007). Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J 30: 951-956 [Abstract] [Full Text]  
• Turnidge, J., Paterson, D. L. (2007). Setting and Revising Antibacterial Susceptibility Breakpoints. Clin. Microbiol. Rev. 20: 391-408 [Abstract] [Full Text]  
• Abgueguen, P., Azoulay-Dupuis, E., Noel, V., Moine, P., Rieux, V., Fantin, B., Bedos, J.-P. (2007). Amoxicillin Is Effective against Penicillin-Resistant Streptococcus pneumoniae Strains in a Mouse Pneumonia Model Simulating Human Pharmacokinetics. Antimicrob. Agents Chemother. 51: 208-214 [Abstract] [Full Text]  
• Falagas, M. E., Siempos, I. I., Bliziotis, I. A., Panos, G. Z. (2006). Impact of Initial Discordant Treatment With {beta}-Lactam Antibiotics on Clinical Outcomes in Adults With Pneumococcal Pneumonia: A Systematic Review. Mayo Clin Proc. 81: 1567-1574 [Abstract] [Full Text]  
• Azoulay-Dupuis, E., Mohler, J., Bedos, J. P., Barau, C., Fantin, B. (2006). Efficacy of Cethromycin, a New Ketolide, against Streptococcus pneumoniae Susceptible or Resistant to Erythromycin in a Murine Pneumonia Model.. Antimicrob. Agents Chemother. 50: 3033-3038 [Abstract] [Full Text]  
• Valles, X., Marcos, A., Pinart, M., Piner, R., Marco, F., Mensa, J. M., Torres, A. (2006). Hospitalized Community-Acquired Pneumonia Due to Streptococcus pneumoniae: Has Resistance to Antibiotics Decreased?. Chest 130: 800-806 [Abstract] [Full Text]  
• Sun, H. K., Nicolau, D. P., Kuti, J. L. (2006). Resource Utilization of Adults Admitted to a Large Urban Hospital With Community-Acquired Pneumonia Caused by Streptococcus pneumoniae.. Chest 130: 807-814 [Abstract] [Full Text]  
• Davis, K. A. (2006). Ventilator-Associated Pneumonia: A Review. J Intensive Care Med 21: 211-226 [Abstract]  
• Aspa, J., Rajas, O., Rodriguez de Castro, F., Huertas, M. C., Borderias, L., Cabello, F. J., Tabara, J., Hernandez-Flix, S., Martinez-Sanchis, A., Torres, A. (2006). Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 27: 1010-1019 [Abstract] [Full Text]  
• Woodhead, M., Blasi, F., Ewig, S., Huchon, G., Leven, M., Ortqvist, A., Schaberg, T., Torres, A., van der Heijden, G., Verheij, T. J. M. (2005). Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 26: 1138-1180 [Abstract] [Full Text]  
• Johnson, A. P., Potz, N., Waight, P., Gungabissoon, U., Livermore, D. M., Pebody, R., Miller, E., George, R. C. (2005). Susceptibility of pneumococci causing meningitis in England and Wales to first-line antimicrobial agents, 2001-2004. J Antimicrob Chemother 56: 1181-1182 [Full Text]  
• Barlow, G, Nathwani, D (2005). Is antibiotic resistance a problem? A practical guide for hospital clinicians. Postgrad. Med. J. 81: 680-692 [Abstract] [Full Text]  
• Grau, I., Pallares, R., Tubau, F., Schulze, M. H., Llopis, F., Podzamczer, D., Linares, J., Gudiol, F., for the Spanish Pneumococcal Infection Study Netwo, (2005). Epidemiologic Changes in Bacteremic Pneumococcal Disease in Patients With Human Immunodeficiency Virus in the Era of Highly Active Antiretroviral Therapy. Arch Intern Med 165: 1533-1540 [Abstract] [Full Text]  
• Kasbekar, N., Acharya, P. S. (2005). Telithromycin: The first ketolide for the treatment of respiratory infections. Am J Health Syst Pharm 62: 905-916 [Abstract] [Full Text]  
• Gracia, M., Martinez-Marin, C., Huelves, L., Gimenez, M. J., Aguilar, L., Carcas, A., Ponte, C., Soriano, F. (2005). Pulmonary Damage and Bacterial Load in Assessment of the Efficacy of Simulated Human Treatment-Like Amoxicillin (2,000 Milligrams) Therapy of Experimental Pneumococcal Pneumonia Caused by Strains for Which Amoxicillin MICs Differ. Antimicrob. Agents Chemother. 49: 996-1001 [Abstract] [Full Text]  
• Azoulay-Dupuis, E., Bedos, J. P., Mohler, J., Moine, P., Cherbuliez, C., Peytavin, G., Fantin, B., Kohler, T. (2005). Activity of Gemifloxacin against Quinolone-Resistant Streptococcus pneumoniae Strains In Vitro and in a Mouse Pneumonia Model. Antimicrob. Agents Chemother. 49: 1046-1054 [Abstract] [Full Text]  
• (2005). Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. Am. J. Respir. Crit. Care Med. 171: 388-416 [Full Text]  
• Pelton, S. I., Hammerschlag, M. R. (2005). Overcoming Current Obstacles in the Management of Bacterial Community-Acquired Pneumonia in Ambulatory Children. CLIN PEDIATR 44: 1-17  
• Amsden, G. W. (2005). Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?. J Antimicrob Chemother 55: 10-21 [Abstract] [Full Text]  
• Wang, J., Barke, R. A., Charboneau, R., Roy, S. (2005). Morphine Impairs Host Innate Immune Response and Increases Susceptibility to Streptococcus pneumoniae Lung Infection. J. Immunol. 174: 426-434 [Abstract] [Full Text]  
• Oteo, J., Lazaro, E., de Abajo, F. J., Baquero, F., Campos, J., Spanish Members of the European Antimicrobial Resi, (2004). Trends in Antimicrobial Resistance in 1,968 Invasive Streptococcus pneumoniae Strains Isolated in Spanish Hospitals (2001 to 2003): Decreasing Penicillin Resistance in Children's Isolates. J. Clin. Microbiol. 42: 5571-5577 [Abstract] [Full Text]  
• Lim, W-S (2004). Identifying failure of empirical treatment for pneumonia: vigilance and common sense. Thorax 59: 918-919 [Full Text]  
• Falco, V., Almirante, B., Jordano, Q., Calonge, L., del Valle, O., Pigrau, C., Planes, A. M., Gavalda, J., Pahissa, A. (2004). Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains?. J Antimicrob Chemother 54: 481-488 [Abstract] [Full Text]  
• File, T. M. Jr, Garau, J., Blasi, F., Chidiac, C., Klugman, K., Lode, H., Lonks, J. R., Mandell, L., Ramirez, J., Yu, V. (2004). Guidelines for Empiric Antimicrobial Prescribing in Community-Acquired Pneumonia. Chest 125: 1888-1901 [Abstract] [Full Text]  
• Maki, D. G. (2004). Pneumococcal Bacteremia: Lessons Learned, Yet More to Learn. Mayo Clin Proc. 79: 599-603  
• Trampuz, A., Widmer, A. F., Fluckiger, U., Haenggi, M., Frei, R., Zimmerli, W. (2004). Changes in the Epidemiology of Pneumococcal Bacteremia in a Swiss University Hospital During a 15-Year Period, 1986-2000. Mayo Clin Proc. 79: 604-612 [Abstract]  
• Azoulay-Dupuis, E., Bedos, J. P., Mohler, J., Schmitt-Hoffmann, A., Schleimer, M., Shapiro, S. (2004). Efficacy of BAL5788, a Prodrug of Cephalosporin BAL9141, in a Mouse Model of Acute Pneumococcal Pneumonia. Antimicrob. Agents Chemother. 48: 1105-1111 [Abstract] [Full Text]  
• Azoulay-Dupuis, E., Bedos, J. P., Mohler, J., Peytavin, G., Isturiz, R., Moine, P., Rieux, V., Cherbuliez, C., Pechere, J. C., Fantin, B., Kohler, T. (2004). Activities of Garenoxacin against Quinolone-Resistant Streptococcus pneumoniae Strains In Vitro and in a Mouse Pneumonia Model. Antimicrob. Agents Chemother. 48: 765-773 [Abstract] [Full Text]  
• Preston, J.A., Beagley, K.W., Gibson, P.G., Hansbro, P.M. (2004). Genetic background affects susceptibility in nonfatal pneumococcal bronchopneumonia. Eur Respir J 23: 224-231 [Abstract] [Full Text]  
• Oosterheert, J. J., Bonten, M. J. M., Hak, E., Schneider, M. M. E., Hoepelman, I. M. (2003). How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review. J Antimicrob Chemother 52: 555-563 [Abstract] [Full Text]  
• Schentag, J. J, Meagher, A. K, Forrest, A. (2003). Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates: Part 1: In Vitro and Animal Models. The Annals of Pharmacotherapy 37: 1287-1298 [Abstract] [Full Text]  
• Knudsen, J. D., Odenholt, I., Erlendsdottir, H., Gottfredsson, M., Cars, O., Frimodt-Moller, N., Espersen, F., Kristinsson, K. G., Gudmundsson, S. (2003). Selection of Resistant Streptococcus pneumoniae during Penicillin Treatment In Vitro and in Three Animal Models. Antimicrob. Agents Chemother. 47: 2499-2506 [Abstract] [Full Text]  
• Balsalobre, L., Ferrandiz, M. J., Linares, J., Tubau, F., de la Campa, A. G. (2003). Viridans Group Streptococci Are Donors in Horizontal Transfer of Topoisomerase IV Genes to Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47: 2072-2081 [Abstract] [Full Text]  
• Zhanel, G. G., DeCorby, M., Noreddin, A., Mendoza, C., Cumming, A., Nichol, K., Wierzbowski, A., Hoban, D. J. (2003). Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. J Antimicrob Chemother 52: 83-88 [Abstract] [Full Text]  
• Zhanel, G. G., Palatnick, L., Nichol, K. A., Bellyou, T., Low, D. E., Hoban, D. J. (2003). Antimicrobial Resistance in Respiratory Tract Streptococcus pneumoniae Isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. 47: 1867-1874 [Abstract] [Full Text]  
• Singer, M. E., Harding, I., Jacobs, M. R., Jaffe, D. H. (2003). Impact of antimicrobial resistance on health outcomes in the out-patient treatment of adult community-acquired pneumonia: a probability model. J Antimicrob Chemother 51: 1269-1282 [Abstract] [Full Text]  
• Martin-Galiano, A. J., de la Campa, A. G. (2003). High-Efficiency Generation of Antibiotic-Resistant Strains of Streptococcus pneumoniae by PCR and Transformation. Antimicrob. Agents Chemother. 47: 1257-1261 [Abstract] [Full Text]  
• de la Campa, A. G., Ferrandiz, M.-J., Tubau, F., Pallares, R., Manresa, F., Linares, J. (2003). Genetic Characterization of Fluoroquinolone-Resistant Streptococcus pneumoniae Strains Isolated during Ciprofloxacin Therapy from a Patient with Bronchiectasis. Antimicrob. Agents Chemother. 47: 1419-1422 [Abstract] [Full Text]  
• Odenholt, I., Gustafsson, I., Lowdin, E., Cars, O. (2003). Suboptimal Antibiotic Dosage as a Risk Factor for Selection of Penicillin-Resistant Streptococcus pneumoniae: In Vitro Kinetic Model. Antimicrob. Agents Chemother. 47: 518-523 [Abstract] [Full Text]  
• Hoffman, H. L., Klepser, M. E., Ernst, E. J., Petzold, C. R., Sa'adah, L. M., Doern, G. V. (2003). Influence of Macrolide Susceptibility on Efficacies of Clarithromycin and Azithromycin against Streptococcus pneumoniae in a Murine Lung Infection Model. Antimicrob. Agents Chemother. 47: 739-746 [Abstract] [Full Text]  
• Noreddin, A. M., Roberts, D., Nichol, K., Wierzbowski, A., Hoban, D. J., Zhanel, G. G. (2002). Pharmacodynamic Modeling of Clarithromycin against Macrolide-Resistant [PCR-Positive mef(A) or erm(B)] Streptococcus pneumoniae Simulating Clinically Achievable Serum and Epithelial Lining Fluid Free-Drug Concentrations. Antimicrob. Agents Chemother. 46: 4029-4034 [Abstract] [Full Text]  
• Metlay, J. P., Shea, J. A., Asch, D. A. (2002). Antibiotic Prescribing Decisions of Generalists and Infectious Disease Specialists: Thresholds for Adopting New Drug Therapies. Med Decis Making 22: 498-505 [Abstract]  
• CANT, A.J., GORDON, S.B., READ, R.C., HART, C.A., WINSTANLEY, C. (2002). Respiratory infections: Proceedings of the Eighth Liverpool Tropical School Bayer Symposium of Microbial Disease held on 3 February 2001. J Med Microbiol 51: 903-914 [Full Text]  
• Varaldo, P. E. (2002). Antimicrobial resistance and susceptibility testing: an evergreen topic. J Antimicrob Chemother 50: 1-4 [Full Text]  
• Klugman, K.P. (2002). Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections. Eur Respir J 20: 3S-8s [Abstract] [Full Text]  
• Martin-Galiano, A. J., Gorgojo, B., Kunin, C. M., de la Campa, A. G. (2002). Mefloquine and New Related Compounds Target the F0 Complex of the F0F1 H+-ATPase of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46: 1680-1687 [Abstract] [Full Text]  
• Casal, J., Aguilar, L., Jado, I., Yuste, J., Gimenez, M. J., Prieto, J., Fenoll, A. (2002). Effects of Specific Antibodies against Streptococcus pneumoniae on Pharmacodynamic Parameters of {beta}-Lactams in a Mouse Sepsis Model. Antimicrob. Agents Chemother. 46: 1340-1344 [Abstract] [Full Text]  
• Bishai, W. (2002). The in vivo-in vitro paradox in pneumococcal respiratory tract infections. J Antimicrob Chemother 49: 433-436 [Full Text]  
• McIntosh, K. (2002). Community-Acquired Pneumonia in Children. NEJM 346: 429-437 [Full Text]  
• Sahm, D. F., Thornsberry, C., Mayfield, D. C., Jones, M. E., Karlowsky, J. A. (2002). In Vitro Activities of Broad-Spectrum Cephalosporins against Nonmeningeal Isolates of Streptococcus pneumoniae: MIC Interpretation Using NCCLS M100-S12 Recommendations. J. Clin. Microbiol. 40: 669-674 [Abstract] [Full Text]  
• (2002). Clinical efficacy of co-trimoxazole versus amoxicillin twice daily for treatment of pneumonia: a randomised controlled clinical trial in Pakistan. Arch. Dis. Child. 86: 113-118 [Abstract] [Full Text]  
• Ball, P., Baquero, F., Cars, O., File, T., Garau, J., Klugman, K., Low, D. E., Rubinstein, E., Wise, R., Consensus Group on Resistance and Prescribing in R, T. (2002). Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 49: 31-40 [Abstract] [Full Text]  
• Reinert, R. R., Al-Lahham, A., Lemperle, M., Tenholte, C., Briefs, C., Haupts, S., Gerards, H. H., Lutticken, R. (2002). Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J Antimicrob Chemother 49: 61-68 [Abstract] [Full Text]  
• (2001). BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 56: iv1-64 [Full Text]  
• Musher, D. M., Bartlett, J. G., Doern, G. V. (2001). A Fresh Look at the Definition of Susceptibility of Streptococcus pneumoniae to {beta}-Lactam Antibiotics. Arch Intern Med 161: 2538-2544 [Abstract] [Full Text]  
• Fass, R. J., Barnishan, J. (2001). Comparison of antimicrobial in vitro activities against Streptococcus pneumoniae independent of MIC susceptibility breakpoints using MIC frequency distribution curves, scattergrams and linear regression analyses. J Antimicrob Chemother 48: 609-615 [Abstract] [Full Text]  
• Waterer, G. W., Somes, G. W., Wunderink, R. G. (2001). Monotherapy May Be Suboptimal for Severe Bacteremic Pneumococcal Pneumonia. Arch Intern Med 161: 1837-1842 [Abstract] [Full Text]  
• Capdevila, O., Pallares, R., Grau, I., Tubau, F., Linares, J., Ariza, J., Gudiol, F. (2001). Pneumococcal Peritonitis in Adult Patients: Report of 64 Cases With Special Reference to Emergence of Antibiotic Resistance. Arch Intern Med 161: 1742-1748 [Abstract] [Full Text]  
• Doern, G. V., Heilmann, K. P., Huynh, H. K., Rhomberg, P. R., Coffman, S. L., Brueggemann, A. B. (2001). Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in the United States during 1999-2000, Including a Comparison of Resistance Rates since 1994-1995. Antimicrob. Agents Chemother. 45: 1721-1729 [Abstract] [Full Text]  
• Niederman, M. S., Mandell, L. A., Anzueto, A., Bass, J. B., Broughton, W. A., Campbell, G. D., Dean, N., File, T., Fine, M. J., Gross, P. A., Martinez, F., Marrie, T. J., Plouffe, J. F., Ramirez, J., Sarosi, G. A., Torres, A., Wilson, R., Yu, V. L. (2001). Guidelines for the Management of Adults with Community-acquired Pneumonia . Diagnosis, Assessment of Severity, Antimicrobial Therapy, and Prevention. Am. J. Respir. Crit. Care Med. 163: 1730-1754 [Full Text]  
• Erlendsdottir, H., Knudsen, J. D., Odenholt, I., Cars, O., Espersen, F., Frimodt-Møller, N., Fuursted, K., Kristinsson, K. G., Gudmundsson, S. (2001). Penicillin Pharmacodynamics in Four Experimental Pneumococcal Infection Models. Antimicrob. Agents Chemother. 45: 1078-1085 [Abstract] [Full Text]  
• Dagan, R., Klugman, K. P., Craig, W. A., Baquero, F. (2001). Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 47: 129-140 [Abstract] [Full Text]  
• Piroth, L., Desbiolles, N., Mateo-Ponce, V., Martin, L., Lequeu, C., Charles, P.-E., Portier, H., Chavanet, P. (2001). HMR 3647 human-like treatment of experimental pneumonia due to penicillin-resistant and erythromycin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 47: 33-42 [Abstract] [Full Text]  
• Duong, M., Simard, M., Bergeron, Y., Bergeron, M. G. (2001). Kinetic Study of the Inflammatory Response in Streptococcus pneumoniae Experimental Pneumonia Treated with the Ketolide HMR 3004. Antimicrob. Agents Chemother. 45: 252-262 [Abstract] [Full Text]  
• Cottagnoud, P., Gerber, C. M., Acosta, F., Cottagnoud, M., Neftel, K., Tauber, M. G. (2000). Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model. J Antimicrob Chemother 46: 981-985 [Abstract] [Full Text]  
• Luna, C. M., Famiglietti, A., Absi, R., Videla, A. J., Nogueira, F. J., Fuenzalida, A. D., Gene, R. J. (2000). Community-Acquired Pneumonia : Etiology, Epidemiology, and Outcome at a Teaching Hospital in Argentina. Chest 118: 1344-1354 [Abstract] [Full Text]  
• Marco, F., Bouza, E., Garcia-de-Lomas, J., Aguilar, L. (2000). Streptococcus pneumoniae in community-acquired respiratory tract infections in Spain: the impact of serotype and geographical, seasonal and clinical factors on its susceptibility to the most commonly prescribed antibiotics. J Antimicrob Chemother 46: 557-564 [Abstract] [Full Text]  
• Gerber, C. M., Tovar, L., Cottagnoud, M., Neftel, K. A., Tauber, M. G., Cottagnoud, P. (2000). Grepafloxacin against penicillin-resistant pneumococci in the rabbit meningitis model. J Antimicrob Chemother 46: 249-253 [Abstract] [Full Text]  
• Jorgensen, J. H., Barry, A. L., Traczewski, M. M., Sahm, D. F., McElmeel, M. L., Crawford, S. A. (2000). Rapid Automated Antimicrobial Susceptibility Testing of Streptococcus pneumoniae by Use of the bioMerieux VITEK 2. J. Clin. Microbiol. 38: 2814-2818 [Abstract] [Full Text]  
• Plouffe, J., Schwartz, D. B., Kolokathis, A., Sherman, B. W., Arnow, P. M., Gezon, J. A., Suh, B., Anzuetto, A., Greenberg, R. N., Niederman, M., Paladino, J. A., Ramirez, J. A., Inverso, J., Knirsch, C. A., the Azithromycin Intravenous Clinical Trials Group, (2000). Clinical Efficacy of Intravenous followed by Oral Azithromycin Monotherapy in Hospitalized Patients with Community-Acquired Pneumonia. Antimicrob. Agents Chemother. 44: 1796-1802 [Abstract] [Full Text]  
• Mandell, L. (2000). Gemifloxacin: survival of the fittest. J Antimicrob Chemother 46: 33-37 [Abstract] [Full Text]  
• Grau, I., Linares, J., Pallares, R. (2000). Epidemiologic Relation between HIV and Invasive Pneumococcal Disease in San Francisco County, California. ANN INTERN MED 132: 1009-1009 [Full Text]  
• Heffelfinger, J. D., Dowell, S. F., Jorgensen, J. H., Klugman, K. P., Mabry, L. R., Musher, D. M., Plouffe, J. F., Rakowsky, A., Schuchat, A., Whitney, C. G., and the Drug-Resistant Streptococcus pneumoniae Th, (2000). Management of Community-Acquired Pneumonia in the Era of Pneumococcal Resistance: A Report From the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 160: 1399-1408 [Abstract] [Full Text]  
• Mohammed, M. J., Tenover, F. C. (2000). Evaluation of the PASCO Strep Plus Broth Microdilution Antimicrobial Susceptibility Panels for Testing Streptococcus pneumoniae and Other Streptococcal Species. J. Clin. Microbiol. 38: 1713-1716 [Abstract] [Full Text]  
• Ferrándiz, M. J., Fenoll, A., Liñares, J., De La Campa, A. G. (2000). Horizontal Transfer of parC and gyrA in Fluoroquinolone-Resistant Clinical Isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 44: 840-847 [Abstract] [Full Text]  
• Amsden, G. W. (2000). Reply. J Antimicrob Chemother 45: 402-403 [Full Text]  
• Harwell, J. I., Brown, R. B. (2000). The Drug-Resistant Pneumococcus: Clinical Relevance, Therapy, and Prevention. Chest 117: 530-541 [Abstract] [Full Text]  
• Naktin, J., DeSimone, J. (1999). Lumbar Vertebral Osteomyelitis with Mycotic Abdominal Aortic Aneurysm Caused by Highly Penicillin-Resistant Streptococcus pneumoniae. J. Clin. Microbiol. 37: 4198-4200 [Abstract] [Full Text]  
• Linares, J., de la Campa, A. G., Pallares, R., Peterson, D. E., Sahm, D. F., Chen, D. K., McGeer, A., Low, D. E. (1999). Fluoroquinolone Resistance in Streptococcus pneumoniae. NEJM 341: 1546-1548 [Full Text]  
• Piroth, L., Martin, L., Coulon, A., Lequeu, C., Duong, M., Buisson, M., Portier, H., Chavanet, P. (1999). Development of a New Experimental Model of Penicillin-Resistant Streptococcus pneumoniae Pneumonia and Amoxicillin Treatment by Reproducing Human Pharmacokinetics. Antimicrob. Agents Chemother. 43: 2484-2492 [Abstract] [Full Text]  
• Sabella, C., Goldfarb, J. (1999). Penicillin-Resistant Pneumococcal Infections. CLIN PEDIATR 38: 609-610  
• Catterall, J R (1999). Lung infections bullet 5: Streptococcus pneumoniae. Thorax 54: 929-937 [Full Text]  
• Bergeron, Y., Ouellet, N., Simard, M., Olivier, M., Bergeron, M. G. (1999). Immunomodulation of Pneumococcal Pulmonary Infection with NG-Monomethyl-L-Arginine. Antimicrob. Agents Chemother. 43: 2283-2290 [Abstract] [Full Text]  
• Siegel, R. E. (1999). The Significance of Serum vs Tissue Levels of Antibiotics in the Treatment of Penicillin-Resistant Streptococcus pneumoniae and Community-Acquired Pneumonia: Are We Looking in the Wrong Place?. Chest 116: 535-538 [Full Text]  
• EWIG, S., RUIZ, M., TORRES, A., MARCO, F., MARTINEZ, J. A., SANCHEZ, M., MENSA, J. (1999). Pneumonia Acquired in the Community Through Drug-Resistant Streptococcus pneumoniae. Am. J. Respir. Crit. Care Med. 159: 1835-1842 [Abstract] [Full Text]  
• Pan, X.-S., Fisher, L. M. (1999). Streptococcus pneumoniae DNA Gyrase and Topoisomerase IV: Overexpression, Purification, and Differential Inhibition by Fluoroquinolones. Antimicrob. Agents Chemother. 43: 1129-1136 [Abstract] [Full Text]  
• Jetté, L. P., Sinave, C. (1999). Use of an Oxacillin Disk Screening Test for Detection of Penicillin- and Ceftriaxone-Resistant Pneumococci. J. Clin. Microbiol. 37: 1178-1181 [Abstract] [Full Text]  
• Campbell, G. D. Jr. (1999). Commentary on the 1993 American Thoracic Society Guidelines for the Treatment of Community-Acquired Pneumonia. Chest 115: 14S-18S [Abstract] [Full Text]  
• (1999). Tackling antimicrobial resistance. DTB 37: 9-16 [Abstract] [Full Text]